Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor in Advanced Cancer Research

Introduction: Redefining Cancer Research with Anlotinib Hydrochloride

As the landscape of anti-angiogenic research and cancer biology evolves, Anlotinib hydrochloride has emerged as a transformative multi-target tyrosine kinase inhibitor (TKI). Developed for research applications, this anti-angiogenic small molecule selectively inhibits VEGFR2, PDGFRβ, and FGFR1—key drivers of tumor angiogenesis and proliferation—while demonstrating nanomolar potency and minimal cytotoxicity. Sourced from APExBIO, Anlotinib hydrochloride (CAS 1058157-76-8) is engineered for reproducibility, safety, and translational relevance in preclinical oncology, pharmacology, and molecular signaling pathway studies.

Principle Overview: Multi-Target Tyrosine Kinase Inhibition

Anlotinib hydrochloride is a next-generation small-molecule TKI designed to disrupt tumor angiogenesis by targeting several receptor tyrosine kinases (RTKs). Its primary mechanism involves selective inhibition of:

• VEGFR2 (Vascular Endothelial Growth Factor Receptor 2): IC₅₀ = 5.6 ± 1.2 nM
• PDGFRβ (Platelet-Derived Growth Factor Receptor Beta): IC₅₀ = 8.7 ± 3.4 nM
• FGFR1 (Fibroblast Growth Factor Receptor 1): IC₅₀ = 11.7 ± 4.1 nM

By blocking these kinases, Anlotinib efficiently inhibits the ERK signaling pathway, thereby suppressing endothelial cell migration, capillary tube formation, and ultimately tumor growth. Unlike first-generation agents such as sunitinib or sorafenib, Anlotinib’s multi-target profile grants broader efficacy across diverse cancer models, including those exhibiting resistance to single-pathway inhibitors.

Pharmacokinetic studies further reveal excellent oral bioavailability (28–58% in rats, 41–77% in dogs), high plasma protein binding (93–97%), and notable blood-brain barrier penetration—making it particularly attractive for central nervous system tumor models. Its metabolism, primarily via CYP3A, ensures manageable drug-drug interaction risks and supports robust preclinical pharmacokinetic profiling.

Experimental Workflow: Optimized Protocols with Anlotinib Hydrochloride

1. Endothelial Cell Migration Inhibition Assay

The endothelial cell migration assay is a gold standard for quantifying anti-angiogenic activity. Utilize human vascular endothelial cells (e.g., EA.hy 926):

1. Cell Seeding: Plate cells at 80% confluence in serum-free medium.
2. Wound Creation: Create a uniform scratch using a sterile pipette tip.
3. Treatment: Incubate cells with various concentrations of Anlotinib (e.g., 0.1–1 μM), alongside VEGF, PDGF-BB, or FGF-2 to stimulate migration.
4. Imaging: Capture images at 0, 12, and 24 hours post-treatment.
5. Analysis: Quantify migration inhibition using image analysis software. Expect potent migration suppression at nanomolar concentrations, with minimal cytotoxicity up to 1 μM.

This workflow directly leverages Anlotinib’s capacity as a VEGFR2, PDGFRβ, and FGFR1 inhibitor—enabling clear attribution of anti-angiogenic effects.

2. Capillary Tube Formation Assay

To model in vitro angiogenesis, the capillary tube formation assay provides high-throughput quantitation:

1. Matrigel Preparation: Coat 96-well plates with growth factor-reduced Matrigel.
2. Cell Seeding: Add endothelial cells (2–3 × 10⁴ cells/well).
3. Treatment: Apply Anlotinib at graded concentrations (0.01–1 μM) in the presence of VEGF, PDGF-BB, or FGF-2.
4. Incubation: Culture for 4–8 hours, then image wells.
5. Analysis: Quantify tube length, branch points, and network complexity. Anlotinib consistently produces dose-dependent inhibition, outperforming sunitinib and nintedanib in published benchmarks [Binding Buffer, 2023].

These functional assays form the backbone of anti-angiogenic research and are highly reproducible with APExBIO-supplied Anlotinib hydrochloride due to its purity and solubility profile.

3. Downstream Signaling Analysis

To confirm ERK signaling pathway inhibition:

• Perform Western blot or ELISA to measure phosphorylated VEGFR2, PDGFRβ, FGFR1, and ERK1/2 levels following Anlotinib treatment.
• Expect robust reductions in phosphorylation at low nanomolar doses, providing mechanistic validation of pathway blockade.

Advanced Applications and Comparative Advantages

Translational Value in Tumor Angiogenesis and Cancer Models

Anlotinib hydrochloride’s efficacy extends well beyond in vitro assays. In vivo studies demonstrate significant tumor growth inhibition and improved survival across diverse cancer models, such as hepatocellular carcinoma, non-small cell lung cancer, and rare tumors. Notably, a case report in OncoTargets and Therapy documents remarkable regression of metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT) following Anlotinib administration, with durable response and manageable side effects. This expands its research relevance into rare and refractory cancer types—an area where multi-target inhibition is particularly valuable.

When compared with first- and second-generation TKIs, Anlotinib exhibits:

• Superior specificity for VEGFR2, PDGFRβ, and FGFR1 (sub-10 nM IC₅₀s)
• Lower cytotoxicity at experimental concentrations
• Greater oral bioavailability and blood-brain barrier penetration
• Reduced risk of confounding off-target toxicity in functional assays

Mechanistic Mastery and Strategic Use complements this narrative by highlighting the unique translational advantages of APExBIO’s Anlotinib for pioneering tumor angiogenesis inhibition and mapping future research directions. Meanwhile, the Multi-Target Tyrosine Kinase Inhibitor Guide offers protocol enhancements and reproducibility strategies—ideal for those optimizing workflow robustness and data quality.

For researchers focusing on advanced cancer models and tissue-specific angiogenesis, Anlotinib’s ability to cross the blood-brain barrier and its favorable preclinical pharmacokinetics (terminal half-life: 5.1 ± 1.6 h in rats; 22.8 ± 11.0 h in dogs) support its use in central nervous system tumor studies and cross-species translation.

Troubleshooting and Optimization Tips

Common Challenges and Solutions

• Solubility Issues: Anlotinib hydrochloride is readily soluble in DMSO. Prepare concentrated stocks (e.g., 10 mM), aliquot, and store at -20°C to avoid freeze-thaw cycles. Dilute into aqueous buffers immediately prior to use.
• Batch-to-Batch Consistency: Always source from a trusted supplier such as APExBIO to ensure chemical consistency, purity, and reproducibility across experiments.
• Cytotoxicity Artifacts: At concentrations below 1 μM, Anlotinib demonstrates negligible non-specific cytotoxicity. Always include vehicle controls and validate with viability assays (e.g., MTT).
• Assay Variability: For migration and tube formation assays, ensure uniform cell seeding and minimize edge effects in multi-well plates. Standardize growth factor concentrations to isolate Anlotinib’s specific effects.
• Pharmacokinetic Modeling: When transitioning from cell-based assays to animal models, factor in high plasma protein binding (93–97%) and potential CYP3A-mediated metabolism. This minimizes surprises in dose-response relationships and supports translational study design.

The Tumor Angiogenesis Application Guide offers expanded troubleshooting for common functional assays, including detailed tips for maximizing data reproducibility and optimizing experimental throughput.

Future Outlook: Expanding the Frontier of Anti-Angiogenic Research

With its unique multi-target mechanism, favorable safety profile, and robust pharmacokinetic characteristics, Anlotinib hydrochloride is poised to drive the next wave of innovation in cancer research. Emerging areas of application include:

• Resistance Mechanisms: Investigating Anlotinib’s role in overcoming resistance to single-pathway TKIs through parallel inhibition of VEGFR, PDGFR, and FGFR signaling pathways.
• Combination Therapies: Exploring synergy with immunotherapies or cytotoxic agents in preclinical models, leveraging Anlotinib’s low drug-drug interaction risk profile.
• Rare and Central Nervous System Tumors: Utilizing its blood-brain barrier penetration to study brain metastasis and glioblastoma models.
• Precision Oncology: Adapting functional assays to patient-derived xenograft (PDX) and organoid models for personalized medicine research.

As highlighted in the IADSRCT case study, Anlotinib’s clinical translation potential is underscored by real-world evidence of efficacy and tolerability in rare, aggressive cancers. Furthermore, comprehensive mechanistic reviews such as Binding Buffer’s in-depth analysis extend the foundation for future translational and preclinical investigations.

Conclusion

APExBIO’s Anlotinib hydrochloride stands as a benchmark tool for advanced anti-angiogenic and cancer research. Its nanomolar potency against VEGFR2, PDGFRβ, and FGFR1, coupled with an exemplary safety profile and pharmacokinetic versatility, empowers researchers to design reproducible, data-rich studies that bridge the gap between bench discovery and translational application. By leveraging actionable workflows, protocol enhancements, and troubleshooting strategies, investigators can maximize the value of this anti-cancer compound in unraveling the complexities of tumor angiogenesis and growth inhibition.

For the latest protocols, product specifications, and ordering information, visit the official Anlotinib hydrochloride product page.